1157 related articles for article (PubMed ID: 15721390)
1. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
2. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1.
Bestman-Smith J; Gourde P; Désormeaux A; Tremblay MJ; Bergeron MG
Biochim Biophys Acta; 2000 Sep; 1468(1-2):161-74. PubMed ID: 11018661
[TBL] [Abstract][Full Text] [Related]
3. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes.
Gagné JF; Désormeaux A; Perron S; Tremblay MJ; Bergeron MG
Biochim Biophys Acta; 2002 Feb; 1558(2):198-210. PubMed ID: 11779569
[TBL] [Abstract][Full Text] [Related]
5. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
6. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments.
Dufresne I; Désormeaux A; Bestman-Smith J; Gourde P; Tremblay MJ; Bergeron MG
Biochim Biophys Acta; 1999 Oct; 1421(2):284-94. PubMed ID: 10518698
[TBL] [Abstract][Full Text] [Related]
7. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
8. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
[TBL] [Abstract][Full Text] [Related]
9. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
10. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
Huwyler J; Yang J; Pardridge WM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
12. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody.
Pan H; Niu GQ; Pan J; Lu WY
Yao Xue Xue Bao; 2006 Jun; 41(6):506-12. PubMed ID: 16927823
[TBL] [Abstract][Full Text] [Related]
13. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
15. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status.
Phillips NC; Gagne L; Tsoukas C; Dahman J
J Immunol; 1994 Mar; 152(6):3168-74. PubMed ID: 7908302
[TBL] [Abstract][Full Text] [Related]
16. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
18. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
20. Targeting cell-free HIV and virally-infected cells with anti-HLA-DR immunoliposomes containing amphotericin B.
Bestman-Smith J; Désormeaux A; Tremblay MJ; Bergeron MG
AIDS; 2000 Nov; 14(16):2457-65. PubMed ID: 11101055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
